BCR-ABL tyrosine kinase domain mutations combinations affects imatinib resistence in chronic phase chronic myelogenous leukemia

Siprianus Ugroseno Yudho Bintoro, P. N.A. Amrita, E. Joewarini, P. Suryohusodo, S. Soebandiri

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'BCR-ABL tyrosine kinase domain mutations combinations affects imatinib resistence in chronic phase chronic myelogenous leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences